ANSWER: B

Rationale:

Ezetimibe selectively inhibits NPC1L1, a sterol transporter located on the apical (brush-border) membrane of small intestinal enterocytes. NPC1L1 is the primary pathway by which free cholesterol — both dietary and biliary — is absorbed from the gut lumen into enterocytes. Blockade of NPC1L1 reduces cholesterol delivery to the liver, which lowers hepatic cholesterol content and — via the SREBP-2 (sterol regulatory element-binding protein 2) pathway — upregulates hepatic LDL receptor expression, accelerating LDL-C clearance from plasma. This mechanism is entirely distinct from statin-mediated inhibition of hepatic de novo synthesis, making ezetimibe a complementary rather than redundant agent. Option A: HMG-CoA reductase inhibition is the mechanism of statins, not ezetimibe. Ezetimibe does not affect hepatic cholesterol synthesis directly and has no activity at this enzyme. Option B: Correct. NPC1L1 on the intestinal brush-border membrane is the direct and selective molecular target of ezetimibe. Option C: ABCG5/G8 is a transporter that secretes sterols back into the intestinal lumen and is relevant to sitosterolemia, but it is not the target of ezetimibe. Ezetimibe does not affect ABCG5/G8 activity. Option D: PCSK9 inhibition is the mechanism of evolocumab, alirocumab, and inclisiran. Ezetimibe has no effect on PCSK9 secretion or activity. Option E: MTP inhibition is the mechanism of lomitapide, an orphan drug used in homozygous familial hypercholesterolemia. Ezetimibe does not affect chylomicron assembly or MTP.

ANSWER: D

Rationale:

Ezetimibe undergoes extensive glucuronide conjugation (glucuronidation) in the intestinal wall and liver, producing ezetimibe-glucuronide, which is pharmacologically active and retains NPC1L1 inhibitory activity. The glucuronide undergoes enterohepatic recirculation — it is excreted in bile into the intestinal lumen and subsequently reabsorbed — a cycle that prolongs the effective plasma and intestinal exposure of the drug and its active metabolite, supporting once-daily dosing at a fixed 10 mg dose. Ezetimibe is minimally metabolized by CYP450 enzymes, which accounts for its extremely low drug-drug interaction potential. Elimination is predominantly fecal. Option A: Ezetimibe is not metabolized by CYP3A4 and does not produce a sulfoxide metabolite. CYP450-independent glucuronidation is the primary metabolic pathway, which is why ezetimibe has minimal drug interaction potential. Option B: Ezetimibe does not accumulate in adipose tissue as a depot. Its prolonged action results from enterohepatic recirculation of the glucuronide metabolite, not tissue accumulation. Option C: Ezetimibe is not acetylated by NAT2. NAT2 acetylation is relevant to drugs such as isoniazid and hydralazine. Ezetimibe's metabolism is via UDP-glucuronosyltransferase (UGT), not acetyltransferase. Option D: Correct. Glucuronide conjugation producing an active metabolite with enterohepatic recirculation is the pharmacokinetic basis for ezetimibe's once-daily dosing and prolonged intestinal exposure. Option E: Ezetimibe is not converted by intestinal bacteria. Its metabolism occurs in the intestinal wall and liver via UGT enzymes. Colonic bacterial metabolism is not part of ezetimibe's pharmacokinetic profile.

ANSWER: A

Rationale:

IMPROVE-IT (2015) enrolled 18,144 patients stabilized after an acute coronary syndrome (ACS) and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. The primary composite endpoint — cardiovascular death, non-fatal myocardial infarction, unstable angina requiring hospitalization, coronary revascularization, and non-fatal stroke — was reduced by a relative 6.4% (34.7% vs. 32.7% absolute event rates) over a median of 6 years, with achieved LDL-C of 53.7 mg/dL in the combination arm versus 69.5 mg/dL in the placebo arm. The trial's landmark importance was twofold: it was the first to confirm that non-statin LDL-C lowering reduces cardiovascular events, validating the lipid hypothesis beyond statins, and it demonstrated that achieving very low LDL-C values is safe with no J-curve effect. Option A: Correct. IMPROVE-IT enrolled post-ACS patients, used simvastatin as the backbone therapy, and demonstrated a statistically significant reduction in the primary composite cardiovascular endpoint with the addition of ezetimibe. Option B: IMPROVE-IT did not compare ezetimibe monotherapy to statin monotherapy, and ezetimibe is not established as a first-line alternative to statins. The trial added ezetimibe on top of statin background therapy. Option C: IMPROVE-IT enrolled post-ACS patients, not patients with familial hypercholesterolemia specifically, and did not use rosuvastatin. The achieved LDL-C in the combination arm was approximately 53.7 mg/dL, not below 30 mg/dL. Option D: IMPROVE-IT enrolled post-ACS patients, not a CKD-specific population. A separate trial (SHARP) examined simvastatin plus ezetimibe in CKD patients and reported a reduction in atherosclerotic events, but that is a different trial with a different design. Option E: IMPROVE-IT did not include evolocumab. It predates the PCSK9 inhibitor outcomes trials (FOURIER, ODYSSEY OUTCOMES) and compared ezetimibe added to statin versus statin plus placebo only.

ANSWER: C

Rationale:

PCSK9 is a secreted serine protease that binds the epidermal growth factor-like repeat A (EGF-A) domain of the LDL receptor on the hepatocyte surface. Under normal receptor recycling, after an LDL particle is internalized via receptor-mediated endocytosis, the LDLR dissociates from LDL in the acidic endosome and recycles to the cell surface for re-use. When PCSK9 is bound to the LDLR, the receptor-PCSK9 complex is routed to the lysosome instead of recycling — resulting in receptor degradation. Fewer surface LDL receptors means less LDL-C clearance from plasma and higher circulating LDL-C. Loss-of-function PCSK9 mutations cause lifelong very low LDL-C and markedly reduced cardiovascular risk, which validated PCSK9 as a therapeutic target. Gain-of-function mutations cause a phenotype resembling familial hypercholesterolemia. Option A: PCSK9 does not enter the nucleus or regulate LDLR transcription. LDL receptor gene expression is controlled by SREBP-2 (sterol regulatory element-binding protein 2). PCSK9 acts post-translationally on the LDLR protein, not at the transcriptional level. Option B: HMG-CoA reductase activity is regulated by SREBP-2, AMPK (AMP-activated protein kinase), and intracellular cholesterol levels. PCSK9 does not phosphorylate or allosterically activate HMG-CoA reductase. Option C: Correct. PCSK9 binds the LDLR on the hepatocyte surface and redirects the internalized receptor-PCSK9 complex to lysosomal degradation, reducing receptor recycling and increasing plasma LDL-C. Option D: PCSK9 does not cleave apoB-100. LDL particle size heterogeneity is determined by triglyceride-rich lipoprotein remodeling and lipase activity, not by PCSK9 proteolytic cleavage of apoB-100. Option E: PCSK9 does not inhibit ABCA1. ABCA1 is a key mediator of cholesterol efflux from macrophages to apoA-I (apolipoprotein A-I), the first step in reverse cholesterol transport. PCSK9 biology is specific to hepatic LDLR regulation.

ANSWER: E

Rationale:

Evolocumab is a fully human IgG2 monoclonal antibody that binds PCSK9 with high affinity in the extracellular space — specifically in the bloodstream — before PCSK9 can engage the EGF-A domain of the LDL receptor on the hepatocyte surface. By sequestering circulating PCSK9, evolocumab prevents the formation of the receptor-PCSK9 complex that would otherwise route internalized LDL receptors to lysosomal degradation. The net result is that LDL receptors recycle normally to the hepatocyte surface, increasing the number of functional receptors available to clear LDL-C from plasma. Evolocumab reduces LDL-C by approximately 55–70% when added to maximally tolerated statin therapy and is administered as a subcutaneous injection either 140 mg every 2 weeks or 420 mg once monthly. Option A: The mechanism described — binding PCSK9 mRNA within the RISC — is the mechanism of inclisiran, a small interfering RNA (siRNA) agent. Evolocumab is a monoclonal antibody that acts extracellularly on the PCSK9 protein, not intracellularly on PCSK9 mRNA. Option B: Evolocumab does not bind the LDL receptor. It binds PCSK9 in the extracellular space. The LDL receptor itself is not the target of any currently approved lipid-lowering monoclonal antibody. Option C: Evolocumab has no activity at NPC1L1 and does not interact with ezetimibe's mechanism. NPC1L1 inhibition is exclusively the domain of ezetimibe. The two agents have completely distinct and non-overlapping targets. Option D: HMG-CoA reductase inhibition is the mechanism of statins. Evolocumab does not enter hepatocytes or interact with HMG-CoA reductase. Evolocumab's mechanism is entirely extracellular, targeting circulating PCSK9 protein. Option E: Correct. Evolocumab binds circulating PCSK9 extracellularly, prevents receptor-PCSK9 complex formation, and allows LDL receptors to recycle normally — the fundamental mechanism by which PCSK9 inhibition increases hepatic LDL-C clearance.

ANSWER: B

Rationale:

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk, 2017) enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) — prior myocardial infarction, stroke, or symptomatic peripheral arterial disease — who were on optimized statin therapy with LDL-C of 70 mg/dL or above. Patients were randomized to evolocumab (140 mg every 2 weeks or 420 mg monthly) versus placebo. Evolocumab reduced LDL-C by approximately 59% from a median baseline of 92 mg/dL to a median of 30 mg/dL. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina) was reduced by a relative 15%, and the key secondary endpoint (cardiovascular death, MI, or stroke) was reduced by 20%. The trial also confirmed the safety of achieving very low LDL-C levels, with no increase in adverse events at median achieved LDL-C of 30 mg/dL. Option A: FOURIER did not enroll statin-naive patients or focus exclusively on familial hypercholesterolemia. All enrolled patients were on background statin therapy with established ASCVD. The LDL-C reduction magnitude and relative risk reduction described do not match FOURIER's reported results. Option B: Correct. FOURIER enrolled 27,564 ASCVD patients on statin therapy, achieved approximately 59% LDL-C reduction to a median of 30 mg/dL, and demonstrated a 15% relative reduction in the primary composite cardiovascular endpoint. Option C: FOURIER was not a head-to-head comparison of evolocumab versus alirocumab. It compared evolocumab versus placebo. No large randomized trial has directly compared the two PCSK9 monoclonal antibodies against each other for cardiovascular outcomes. Option D: FOURIER compared evolocumab to placebo, not to ezetimibe, and was not restricted to a diabetic population. A diabetes subgroup analysis was performed post hoc but the trial design was not diabetes-specific. Option E: FOURIER did not include inclisiran and did not compare the two agents. Inclisiran was in earlier clinical development at the time of FOURIER and is not an active comparator in that trial.

ANSWER: D

Rationale:

ODYSSEY OUTCOMES (2018) enrolled 18,924 patients who had experienced an acute coronary syndrome (ACS) — myocardial infarction or unstable angina — within 1 to 12 months prior to randomization, all of whom were on high-intensity or maximally tolerated statin therapy. Alirocumab (75 mg or 150 mg subcutaneously every 2 weeks, with blinded dose adjustment) reduced LDL-C by approximately 55% from a median baseline of 87 mg/dL. The primary composite endpoint — coronary heart disease death, non-fatal MI, ischemic stroke, or unstable angina requiring hospitalization — was significantly reduced. Importantly, a pre-specified analysis demonstrated a reduction in all-cause mortality in the subgroup of patients with baseline LDL-C above 100 mg/dL, a finding not seen in FOURIER and one that strengthens the case for early, aggressive LDL-C lowering in very high-risk post-ACS patients. Option A: ODYSSEY OUTCOMES did not compare alirocumab to ezetimibe. It compared alirocumab to placebo on a background of high-intensity statin therapy. The enrolled population was post-ACS, not stable coronary artery disease. Option B: ODYSSEY OUTCOMES was not restricted to genetically confirmed familial hypercholesterolemia patients. It enrolled a broad post-ACS population. The percentage achieving LDL-C below 25 mg/dL and the all-cause mortality finding described do not match the trial's reported results. Option C: ODYSSEY OUTCOMES enrolled post-ACS patients, not patients with stable peripheral arterial disease. Limb ischemia events were not a primary or major secondary endpoint in this trial. Option D: Correct. ODYSSEY OUTCOMES enrolled post-ACS patients on high-intensity statin therapy, demonstrated significant reduction in the primary composite cardiovascular endpoint with alirocumab, and showed a pre-specified mortality benefit in the highest-LDL subgroup — a distinguishing feature from FOURIER. Option E: ODYSSEY OUTCOMES was not a stroke-specific trial and did not enroll a recent ischemic stroke population. Ischemic stroke was included as a component of the primary composite endpoint but was not the entry criterion or primary focus of the trial.

ANSWER: A

Rationale:

Inclisiran is a synthetic siRNA molecule conjugated to triantennary GalNAc (N-acetylgalactosamine), which mediates selective uptake by hepatocytes via asialoglycoprotein receptors (ASGPR) on the hepatocyte surface. Once endocytosed, inclisiran is released into the cytoplasm and loaded into the RISC, the cellular enzyme complex responsible for RNA interference. Within the RISC, inclisiran's antisense strand guides sequence-specific recognition and endonucleolytic cleavage of PCSK9 mRNA, preventing its translation into PCSK9 protein. The result is durable suppression of hepatic PCSK9 synthesis, increased LDL receptor recycling, and LDL-C reduction of approximately 50% from baseline. Because inclisiran acts intracellularly to silence PCSK9 mRNA rather than extracellularly to capture secreted PCSK9 protein, it produces more durable suppression and enables twice-yearly dosing after the initial loading doses. Option A: Correct. Inclisiran uses GalNAc-mediated hepatocyte uptake, RISC-mediated PCSK9 mRNA silencing, and acts intracellularly at the translational level — a mechanistic class entirely distinct from the extracellular protein-binding approach of the monoclonal antibodies. Option B: Inclisiran is not an antisense oligonucleotide and does not act at the transcriptional level in the nucleus. It is a double-stranded siRNA molecule that acts post-transcriptionally in the cytoplasm via RISC-mediated mRNA cleavage. Option C: Inclisiran does not enter cells via OATP transporters and does not cause proteasomal degradation of misfolded PCSK9. OATP-mediated hepatic uptake is relevant to statins (particularly rosuvastatin and pravastatin). Inclisiran entry is via ASGPR-mediated endocytosis. Option D: Inclisiran does not bind the same extracellular PCSK9 epitope as the monoclonal antibodies. Its mechanism is intracellular RNA silencing, not extracellular protein sequestration. The duration of its effect results from the stability of the RISC complex and the half-life of silenced mRNA turnover, not from higher binding affinity for secreted PCSK9 protein. Option E: Inclisiran does not activate the complement system and is not a chimeric RNA-DNA oligonucleotide. Its mechanism is entirely dependent on intracellular RISC loading and mRNA cleavage within hepatocytes. Complement-mediated degradation plays no role in its pharmacology.

ANSWER: C

Rationale:

Statins inhibit HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase), the rate-limiting enzyme in hepatic de novo cholesterol synthesis. The resulting decrease in intracellular hepatic cholesterol activates SREBP-2, which upregulates LDL receptor expression and accelerates LDL-C clearance from plasma. Ezetimibe inhibits NPC1L1 on the intestinal brush-border membrane, blocking the absorption of dietary and biliary cholesterol and reducing cholesterol delivery to the liver from a completely different source. Because these two mechanisms target distinct and complementary steps — hepatic synthesis versus intestinal absorption — their combination reduces hepatic cholesterol availability from both routes simultaneously, producing additive LDL-C lowering. In clinical practice, adding ezetimibe to maximally tolerated statin reduces LDL-C by an additional 18–25% on top of whatever reduction the statin has already achieved, as demonstrated in IMPROVE-IT and multiple pharmacodynamic studies. Option A: Ezetimibe does not inhibit CYP3A4 and does not increase rosuvastatin plasma concentrations. Rosuvastatin is minimally metabolized by CYP enzymes; its primary metabolic pathway is via CYP2C9. Ezetimibe's lack of CYP450 interaction is one of its key pharmacological advantages. Option B: Statins do modestly increase PCSK9 secretion as a compensatory response to intracellular cholesterol depletion — this is a known limitation that partially offsets statin efficacy — but ezetimibe does not further upregulate PCSK9. The physiological consequence of statin-induced PCSK9 upregulation is a reduction in LDL receptor density, which is one rationale for adding a PCSK9 inhibitor on top of statin therapy. Option C: Correct. Statins target hepatic cholesterol synthesis; ezetimibe targets intestinal cholesterol absorption. These are mechanistically distinct and complementary pathways, producing additive LDL-C lowering when combined. Option D: Ezetimibe does not inhibit HMG-CoA reductase in any compartment. Its exclusive molecular target is NPC1L1. There is no HMG-CoA reductase inhibitory activity associated with ezetimibe. Option E: Ezetimibe does not activate FXR (farnesoid X receptor) and does not stimulate bile acid synthesis. FXR is a nuclear receptor involved in bile acid homeostasis and is the target of obeticholic acid, a drug used in primary biliary cholangitis. This is not part of ezetimibe's mechanism of action.

ANSWER: E

Rationale:

Evolocumab (Repatha) is approved for subcutaneous administration in two equivalent dosing regimens for most indications: 140 mg every 2 weeks administered as a single injection, or 420 mg once monthly administered as three consecutive 140 mg injections given within 30 minutes. Both regimens produce equivalent LDL-C lowering of approximately 55–70% on background statin therapy and are interchangeable based on patient preference and adherence considerations. The monthly 420 mg option may be preferred by patients who find less frequent injections more convenient; the every-2-week option uses a smaller injection volume per administration. For homozygous familial hypercholesterolemia (HoFH), the dose is 420 mg monthly, with the option to increase to 420 mg every 2 weeks if response is inadequate. Option A: A monthly-only dosing restriction is incorrect. Evolocumab is approved in both the every-2-week (140 mg) and once-monthly (420 mg) regimens for most indications. The prescribing information explicitly describes both options. Option B: Evolocumab is not administered by intravenous infusion. It is exclusively a subcutaneous injection available in both the standard and HoFH indications. Intravenous administration is not an approved route for evolocumab. Option C: Evolocumab is not dosed every 3 months and does not form a subcutaneous depot. A 3-month dosing interval is characteristic of inclisiran (after the initial loading doses), not evolocumab. Evolocumab does not have slow-release depot pharmacokinetics. Option D: Evolocumab is not administered daily and does not have an 11–17 hour half-life. As a full-length IgG2 monoclonal antibody, evolocumab has a plasma half-life of approximately 11–17 days (not hours), which is typical for therapeutic IgG antibodies and supports 2-week to monthly dosing intervals. Option E: Correct. Both 140 mg every 2 weeks and 420 mg once monthly are approved, equivalent regimens for evolocumab in most indications, with the monthly dose delivered as three consecutive 140 mg injections.

ANSWER: B

Rationale:

The patient in Option A: This patient has intermediate ASCVD risk (10-year risk 7.5–19.9%) and has not yet been uptitrated to maximally tolerated statin therapy — an essential prerequisite before adding non-statin agents per guidelines. The appropriate next step is to optimize statin therapy before considering a PCSK9 inhibitor. Option B: Correct. HeFH plus established ASCVD plus LDL-C above target despite maximally tolerated statin plus ezetimibe is the paradigmatic indication for PCSK9 inhibitor addition. Both the risk level and the sequential step-up of therapy are consistent with current guidelines and FDA labeling. Option C: This patient has diabetes with intermediate ASCVD risk and no prior events; her LDL-C of 82 mg/dL may already meet her guideline target (below 70 mg/dL for high-risk without prior events per some risk-enhancer frameworks). Adding a PCSK9 inhibitor in this context would be premature and not consistent with current guideline thresholds, which reserve PCSK9 inhibitors for very high-risk patients who remain above target on statin plus ezetimibe. Option D: Statin intolerance with no prior cardiovascular events and no confirmed FH represents a legitimate but less compelling indication. The 2018 ACC/AHA guideline recommends attempting at least two statins before declaring intolerance and places PCSK9 inhibitors lower in the algorithm for primary prevention without FH. This patient would benefit from further statin rechallenge strategies before PCSK9 inhibitor consideration. Option E: Moderate CKD with no prior cardiovascular events and no FH does not represent a strong PCSK9 inhibitor indication under current guidelines. The appropriate approach is to optimize the statin (within renal dose limits) and add ezetimibe before considering a PCSK9 inhibitor in a primary prevention CKD patient.

• Option B: Option B represents the clearest and strongest indication for PCSK9 inhibitor therapy: he has heterozygous familial hypercholesterolemia (HeFH), very high cardiovascular risk defined by both the genetic condition and a recent myocardial infarction, and remains above the guideline-recommended LDL-C target of below 55 mg/dL despite maximally tolerated statin plus ezetimibe — the exact therapeutic sequence specified by the ACC/AHA 2018 cholesterol guidelines for very high-risk patients. FDA-approved indications for evolocumab and alirocumab include adults with established ASCVD or HeFH as an adjunct to diet and maximally tolerated statin therapy. The combination of both HeFH and established ASCVD places this patient at the highest risk category with the strongest evidence for PCSK9 inhibitor benefit.

ANSWER: A

Rationale:

Ezetimibe has an excellent tolerability profile that is directly relevant to this clinical scenario. In randomized controlled trials including IMPROVE-IT — which enrolled 18,144 patients followed for a median of 6 years — the rates of myalgia, gastrointestinal adverse effects, and headache with ezetimibe were not significantly different from placebo. Importantly, ezetimibe is not associated with hepatotoxicity, new-onset diabetes mellitus, or CYP450-mediated drug-drug interactions. Unlike statins, ezetimibe does not deplete mitochondrial CoQ10 and has no established mechanism for causing or worsening myopathy. This makes it the logical first add-on agent in a patient who already has statin-associated myalgia, as it will not compound the muscle symptom burden. No routine CK or liver function monitoring is required for ezetimibe. Option A: Correct. Ezetimibe's adverse effect rates are not significantly different from placebo, it has no CYP450 interactions, no hepatotoxicity, no diabetes risk, and the long-term IMPROVE-IT data provide robust safety reassurance — all directly applicable to this patient's concerns. Option B: Ezetimibe does not inhibit CoQ10 synthesis and is not associated with an increased risk of myopathy when added to statin therapy. This mechanism of muscle toxicity applies to statins, not ezetimibe. Routine CK monitoring is not recommended for ezetimibe. Option C: Ezetimibe is not a CYP3A4 inhibitor and does not increase plasma concentrations of simvastatin, atorvastatin, or lovastatin. Ezetimibe's metabolism is via UGT (glucuronidation), not CYP450, giving it an extremely low drug-drug interaction potential. No statin dose reduction is required when ezetimibe is added. Option D: Ezetimibe is not associated with increased risk of new-onset type 2 diabetes. This risk is a class effect of statins, not of ezetimibe. NPC1L1 inhibition in pancreatic beta cells is not a recognized mechanism of ezetimibe-related metabolic adverse effects, and no clinical trial data support a diabetogenic effect for ezetimibe. Option E: Ezetimibe is not associated with dose-dependent transaminase elevation, and routine liver function testing is not required for patients on ezetimibe. This monitoring requirement applies to older lipid-lowering agents such as niacin; it is not part of ezetimibe's prescribing information for standard use.

ANSWER: D

Rationale:

Inclisiran (Leqvio) is administered as subcutaneous injections of 284 mg on day 1, day 90 (3 months), and then every 6 months thereafter. This twice-yearly maintenance schedule reflects the mechanism of RNA interference: once the siRNA is incorporated into the RISC within hepatocytes, it directs sustained cleavage of PCSK9 mRNA. Because PCSK9 mRNA silencing is durable — the RISC complex is stable and continues to cleave newly transcribed PCSK9 mRNA for approximately 6 months — re-dosing every 6 months is sufficient to maintain LDL-C suppression of approximately 50% from baseline. The initial day 1 and day 90 doses serve as loading doses that rapidly establish maximal PCSK9 mRNA silencing, after which semi-annual maintenance dosing sustains the effect. This dramatically less frequent dosing schedule compared to evolocumab (every 2 weeks or monthly) represents a meaningful adherence advantage for many patients. Option A: Monthly dosing for 3 months followed by every-2-month maintenance is not the approved inclisiran schedule. This schedule does not match the ORION trial-validated or FDA-approved regimen. The approved maintenance interval is every 6 months, not every 2 months. Option B: A single annual dose is not the approved regimen. Inclisiran requires two initial doses 3 months apart, then semi-annual dosing. The mechanism of action does not involve lipid droplet accumulation — the GalNAc conjugate is a targeting ligand for ASGPR-mediated endocytosis, not a depot-forming component. Option C: Every-2-week initial dosing followed by monthly maintenance is the dosing schedule of alirocumab (in some protocols) or evolocumab, not inclisiran. Inclisiran does not require ASGPR saturation with frequent early dosing — its loading phase consists of two injections 3 months apart. Option D: Correct. Day 1, day 90, then every 6 months is the FDA-approved inclisiran schedule, reflecting the approximately 6-month durability of RISC-mediated PCSK9 mRNA silencing. Option E: Inclisiran does require a loading phase — specifically the day 1 and day 90 initial doses — before transitioning to semi-annual maintenance. The absence of a loading dose description is incorrect. Additionally, the monoclonal antibodies do not formally require "loading doses" in the same pharmacological sense; they achieve steady-state through their regular dosing intervals.

ANSWER: C

Rationale:

Ezetimibe became available as a generic medication in the United States in 2017 and is now widely available at very low cost — typically below $20 per month at most retail pharmacies, and often covered with minimal cost-sharing under standard pharmacy benefit plans. PCSK9 inhibitors (evolocumab and alirocumab), by contrast, carry list prices in the range of $5,000–$7,000 per year (after negotiated rebates, net costs vary), and have historically faced substantial access barriers including prior authorization requirements, step therapy mandates (requiring documented failure or intolerance of maximally tolerated statin plus ezetimibe), and high initial denial rates from commercial insurers. These cost and access differentials are explicitly recognized in the ACC/AHA 2018 cholesterol guideline, which recommends adding ezetimibe as the first non-statin agent before escalating to PCSK9 inhibitors in patients not at LDL-C goal on statin therapy. Option A: The cost description is inverted. Ezetimibe is generic and inexpensive; PCSK9 inhibitors are not generic and carry high list prices. PCSK9 inhibitors do not have broad prior-authorization-free coverage in the US commercial insurance market. Option B: The pricing parity described is incorrect. Generic ezetimibe costs a fraction of what PCSK9 inhibitors cost. The access barrier for PCSK9 inhibitors is primarily cost and prior authorization, not a specialist prescribing requirement — any licensed prescriber can write for these agents. Option C: Correct. Generic ezetimibe is inexpensive and readily accessible; PCSK9 inhibitors require prior authorization and carry high list prices, creating a cost and access differential that informs the guideline-recommended sequential approach of adding ezetimibe before PCSK9 inhibitors. Option D: While FOURIER and ODYSSEY OUTCOMES demonstrated significant cardiovascular event reduction, the absolute event reductions must be weighed against the substantially higher cost of PCSK9 inhibitors relative to ezetimibe. Guidelines do not recommend bypassing ezetimibe in favor of direct PCSK9 inhibitor use in all very high-risk patients; prior authorization requirements remain common regardless of the outcomes evidence. Option E: Ezetimibe is available as a generic at standard retail pharmacies and does not require specialty pharmacy dispensing. PCSK9 inhibitors, as biologic agents requiring refrigeration and subcutaneous administration, are typically dispensed through specialty pharmacy channels — the description in this option reverses the correct situation.

ANSWER: E

Rationale:

The response to evolocumab in homozygous familial hypercholesterolemia depends critically on the underlying mutation type and residual LDL receptor function. HoFH patients with receptor-defective mutations retain some residual LDLR activity — typically 1–25% of normal — and can derive meaningful LDL-C reduction from PCSK9 inhibition by maximizing recycling of the residual functional receptors that would otherwise be degraded. In the TESLA trial evaluating evolocumab in HoFH, patients with receptor-defective mutations (as opposed to receptor-negative mutations) showed significantly greater LDL-C reductions. Patients who are truly receptor-negative (no functional LDL receptors whatsoever) have no target for PCSK9 inhibitor-mediated benefit, since the entire mechanism of PCSK9 inhibition depends on preventing degradation of LDL receptors that must be present to recycle. For these patients, MTP inhibitors (lomitapide) or LDL apheresis remain important options. Triple therapy combining statin, ezetimibe, and evolocumab is a rational approach in receptor-defective HoFH but requires mutation-type awareness to predict response. Option A: The statement that evolocumab produces no LDL-C lowering in all HoFH patients is incorrect. While truly receptor-negative HoFH patients respond poorly, receptor-defective HoFH patients retain residual LDLR function and can benefit. The blanket exclusion of evolocumab in all HoFH is not consistent with the TESLA trial data or current prescribing practice. Option B: PCSK9 inhibition does not act independently of LDL receptor number. Its mechanism is entirely dependent on increasing LDL receptor surface density by preventing receptor degradation. In HoFH patients, evolocumab does not produce the same magnitude of LDL-C reduction as in HeFH patients, precisely because the receptor pool is severely depleted. The claim of receptor-independent LDL-C lowering via a "direct hepatic uptake mechanism" does not reflect PCSK9 inhibitor pharmacology. Option C: Triple therapy does not reliably reduce LDL-C below 70 mg/dL in all HoFH patients regardless of mutation type. Receptor-negative HoFH patients typically achieve minimal response to PCSK9 inhibitors, and LDL apheresis remains an important option for many HoFH patients not adequately controlled with pharmacotherapy alone. Option D: Adding evolocumab to statin plus ezetimibe does produce clinically meaningful additional LDL-C reduction in patients with HeFH and established ASCVD who remain above target — this is well established in clinical practice and trials. The claim that PCSK9 inhibitors provide only non-lipid anti-inflammatory benefit at this point in therapy is not supported by evidence. Option E: Correct. Residual LDL receptor function in receptor-defective HoFH is the key determinant of evolocumab response; receptor-negative HoFH patients with no functional LDLR derive minimal benefit from PCSK9 inhibition, while receptor-defective patients can achieve meaningful additional LDL-C reduction from triple therapy.

ANSWER: B

Rationale:

Ezetimibe undergoes extensive glucuronide conjugation in both the intestinal wall and the liver; the resulting ezetimibe-glucuronide is pharmacologically active and undergoes enterohepatic recirculation, with elimination predominantly via feces. In severe hepatic impairment (Child-Pugh class C), glucuronidation capacity is substantially reduced, resulting in markedly increased plasma exposure of both ezetimibe and ezetimibe-glucuronide relative to patients with normal hepatic function. Because the pharmacokinetic consequences in this population are unpredictable and the safety of markedly elevated exposures has not been adequately studied, ezetimibe is not recommended in patients with severe hepatic impairment per its prescribing information. Mild hepatic impairment (Child-Pugh class A) does not meaningfully alter ezetimibe pharmacokinetics and requires no dose adjustment. Moderate impairment (Child-Pugh class B) results in intermediate exposure increases; use is generally avoided. In the clinical scenario presented, ezetimibe should not be added to this Child-Pugh class C patient's regimen. Option A: Ezetimibe is not eliminated entirely by renal excretion. Its primary elimination route is biliary-fecal, and its primary metabolic pathway is hepatic and intestinal glucuronidation. Hepatic impairment does significantly affect ezetimibe pharmacokinetics, and the Child-Pugh class C restriction is explicit in the prescribing information. Option B: Correct. Glucuronidation impairment in severe hepatic disease increases ezetimibe and ezetimibe-glucuronide plasma exposure substantially, making ezetimibe use not recommended in Child-Pugh class C patients per prescribing information. Option C: Ezetimibe is not contraindicated in all degrees of hepatic impairment. Child-Pugh class A (mild) does not require restriction. The mechanism described — NPC1L1 inhibition precipitating acute-on-chronic liver failure through impaired biliary cholesterol secretion — is not a recognized clinical risk or pharmacological mechanism associated with ezetimibe use in liver disease. Option D: Ezetimibe does not have a 5 mg dose formulation, and dose reduction is not the recommended management strategy for hepatic impairment. The prescribing guidance is to avoid use in moderate-to-severe hepatic impairment (Child-Pugh B and C), not to reduce the dose to 5 mg. Option E: While ezetimibe has a lower hepatotoxicity risk than statins, it is not preferred unconditionally in severe hepatic impairment. The recommendation not to use ezetimibe in Child-Pugh class C explicitly contradicts the claim that it can be used at the standard dose without restriction in decompensated cirrhosis.